Details of Disease

General Information of Disease (ID: DISNHHCN)

• Disease Name: Duodenal ulcer
• Synonyms: stress Ulcer; curling's ulcers; curling Ulcer; duodenal ulcer (disease)
• Disease Class: DA63: Duodenal ulcer
• Definition: An ulcer in the duodenal wall.
• Disease Hierarchy:
  DISL8XZI: Peptic ulcer
  DISZPJLZ: Duodenal disorder
  DISNHHCN: Duodenal ulcer
• ICD Code:
  ICD-11: ICD-11: DA63
  Expand ICD-11: 'DA63
  Expand ICD-10: 'K26; 'K26.0; 'K26.1; 'K26.2; 'K26.3; 'K26.4; 'K26.5; 'K26.6; 'K26.7; 'K26.9
• Disease Identifiers:
  MONDO ID: MONDO_0005412
  MESH ID: D004381
  UMLS CUI: C0013295
  MedGen ID: 41670
  HPO ID: HP:0002588
  SNOMED CT ID: 51868009

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 1 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Ethoxzolamide	DMVO4ED	Approved	Small molecular drug	[1]

This Disease is Treated as An Indication in 3 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
GASTRAZOLE	DMO3ITF	Phase 3	Small molecular drug	[2]
ME-3407	DMO84TL	Phase 2	Small molecular drug	[3]
YH-4808	DMCHFB0	Phase 2	NA	[4]

This Disease is Treated as An Indication in 6 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Ebrotidine	DMV5KR3	Withdrawn from market	Small molecular drug	[5]
KU-1257	DMZMFX6	Discontinued in Phase 3	Small molecular drug	[6]
Osutidine	DMN7TL8	Discontinued in Phase 3	Small molecular drug	[7]
PUMAPRAZOLE	DMB069L	Discontinued in Phase 3	Small molecular drug	[8]
AR-H047108	DMBTG8J	Discontinued in Phase 2	NA	[9]
IGN-2098	DMU4N1O	Discontinued in Phase 2	Small molecular drug	[10]

This Disease is Treated as An Indication in 1 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Ilatreotide	DMPIV1G	Investigative	NA	[11]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 15 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
PSCA	TT9T4AV	Limited	Genetic Variation	[12]
CYP2C19	TTZ58XG	moderate	Genetic Variation	[13]
GAST	TT4LRVO	moderate	Altered Expression	[14]
LY6D	TTINE9B	moderate	Genetic Variation	[15]
LY6K	TT5GKHN	moderate	Genetic Variation	[15]
PLA2G4A	TTT1JVS	moderate	Genetic Variation	[16]
ATP4A	TTF1QVM	Strong	Biomarker	[17]
CFTR	TTRLZHP	Strong	Altered Expression	[18]
HNMT	TT2B6EV	Strong	Genetic Variation	[19]
LTA	TTP73TM	Strong	Genetic Variation	[20]
NOS2	TTF10I9	Strong	Biomarker	[21]
SLC11A2	TT2IS7P	Strong	Biomarker	[22]
TFRC	TT8MG4S	Strong	Biomarker	[22]
TLR5	TTCXP8J	Strong	Genetic Variation	[23]
PGC	TT7K6AD	Definitive	Genetic Variation	[24]

This Disease Is Related to 2 DTP Molecule(s)

Gene Name	DTP ID	Evidence Level	Mode of Inheritance	REF
ATP12A	DT5NLZA	Strong	Biomarker	[17]
SLC26A6	DTVGOLN	Strong	Altered Expression	[18]

This Disease Is Related to 2 DME Molecule(s)

Gene Name	DME ID	Evidence Level	Mode of Inheritance	REF
ABO	DESIA7R	moderate	Genetic Variation	[25]
DTYMK	DEOTVYU	Definitive	Biomarker	[26]

This Disease Is Related to 8 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
MUC6	OTPVL723	Disputed	Biomarker	[27]
EYS	OT0NBPL5	moderate	Genetic Variation	[15]
HLA-DPA1	OT7OG7Y2	moderate	Biomarker	[28]
JRK	OTO8E77P	moderate	Genetic Variation	[15]
ACO1	OT2VUR7L	Strong	Biomarker	[22]
DDX53	OTHK3EGZ	Strong	Biomarker	[29]
ALKBH1	OTADGU5D	Definitive	Biomarker	[30]
FUCA2	OTY5NVMJ	Definitive	Biomarker	[31]

References

• [1] The development of topically acting carbonic anhydrase inhibitors as antiglaucoma agents. Curr Pharm Des. 2008;14(7):649-54.
• [2] Gastrazole (JB95008), a novel CCK2/gastrin receptor antagonist, in the treatment of advanced pancreatic cancer: results from two randomised controlled trials. Br J Cancer. 2006 Apr 24;94(8):1107-15.
• [3] ME-3407, a new antiulcer agent, inhibits acid secretion by interfering with redistribution of H(+)-K(+)-ATPase. Am J Physiol. 1997 May;272(5 Pt 1):G1122-34.
• [4] ClinicalTrials.gov (NCT01538849) Study to Investigate the Safety, Tolerability and Efficacy of YH4808 in Patients With Reflux Esophagitis. U.S. National Institutes of Health.
• [5] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001139)
• [6] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001852)
• [7] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002012)
• [8] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005537)
• [9] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013302)
• [10] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001447)
• [11] Inhibitory effect of intraduodenal administration of somatostatin analogue SDZ CO 611 on rat pancreatic exocrine secretion. Pancreas. 1993 Jul;8(4):471-5.
• [12] Impact of PSCA Polymorphisms on the Risk of Duodenal Ulcer.J Epidemiol. 2021 Jan 5;31(1):12-20. doi: 10.2188/jea.JE20190184. Epub 2019 Dec 14.
• [13] Genetic polymorphism of CYP2C19 & therapeutic response to proton pump inhibitors.Indian J Med Res. 2008 Jun;127(6):521-30.
• [14] Transcriptional expression of gastrin mRNA in Helicobacter pylori infected patients.Indian J Med Res. 1997 Mar;105:136-40.
• [15] A genome-wide association study identifies two susceptibility loci for duodenal ulcer in the Japanese population.Nat Genet. 2012 Mar 4;44(4):430-4, S1-2. doi: 10.1038/ng.1109.
• [16] Bleeding diathesis and gastro-duodenal ulcers in inherited cytosolic phospholipase-A2 alpha deficiency. Thromb Haemost. 2014 Dec;112(6):1182-9. doi: 10.1160/TH14-04-0352. Epub 2014 Aug 7.
• [17] Ilaprazole Compared With Rabeprazole in the Treatment of Duodenal Ulcer: A Randomized, Double-blind, Active-controlled, Multicenter Study.J Clin Gastroenterol. 2019 Oct;53(9):641-647. doi: 10.1097/MCG.0000000000001186.
• [18] Helicobacter pylori infection downregulates duodenal CFTR and SLC26A6 expressions through TGF signaling pathway. BMC Microbiol. 2018 Aug 17;18(1):87.
• [19] C314T polymorphism in histamine N-methyltransferase gene and susceptibility to duodenal ulcer in Chinese population. Clin Chim Acta. 2008 Mar;389(1-2):51-4.
• [20] Polymorphisms in TNF and HSP-70 show a significant association with gastric cancer and duodenal ulcer.Int J Cancer. 2010 Apr 15;126(8):1861-1868. doi: 10.1002/ijc.24773.
• [21] Role of endogenous nitric oxide (NO) and NO synthases in healing of indomethacin-induced intestinal ulcers in rats.Life Sci. 2007 Jan 2;80(4):329-36. doi: 10.1016/j.lfs.2006.09.016. Epub 2006 Sep 23.
• [22] Role of iron in the pathogenesis of cysteamine-induced duodenal ulceration in rats.Am J Physiol Gastrointest Liver Physiol. 2009 Jun;296(6):G1277-86. doi: 10.1152/ajpgi.90257.2008. Epub 2009 Apr 2.
• [23] Polymorphisms in TLR9 but not in TLR5 increase the risk for duodenal ulcer and alter cytokine expression in the gastric mucosa.Innate Immun. 2015 Oct;21(7):706-13. doi: 10.1177/1753425915587130. Epub 2015 May 20.
• [24] Genetic heterogeneity of combined gastric and duodenal ulcers detected by pepsinogen C gene polymorphism.J Gastroenterol Hepatol. 1994 Jul-Aug;9(4):334-9. doi: 10.1111/j.1440-1746.1994.tb01251.x.
• [25] Impact of PSCA variation on gastric ulcer susceptibility.PLoS One. 2013 May 21;8(5):e63698. doi: 10.1371/journal.pone.0063698. Print 2013.
• [26] Identification of H. pylori strain specific DNA sequences between two clinical isolates from NUD and gastric ulcer by SSH.World J Gastroenterol. 2003 Aug;9(8):1747-51. doi: 10.3748/wjg.v9.i8.1747.
• [27] Quantitative MUC5AC and MUC6 mucin estimations in gastric mucus by a least-squares minimization method.Anal Biochem. 2013 Aug 15;439(2):204-11. doi: 10.1016/j.ab.2013.04.013. Epub 2013 Apr 30.
• [28] Contribution of major histocompatibility complex genes to susceptibility and resistance in Helicobacter pylori related diseases.Eur J Gastroenterol Hepatol. 1999 Aug;11(8):875-80. doi: 10.1097/00042737-199908000-00011.
• [29] Prevalence of Helicobacter pylori vacA, cagA, cagE, iceA, babA2 genotypes and correlation with clinical outcome in Turkish patients with dyspepsia.Helicobacter. 2006 Dec;11(6):574-80. doi: 10.1111/j.1523-5378.2006.00461.x.
• [30] Hereditary aspects of duodenal ulceration: pepsin 1 secretion in relation to ABO blood groups and ABH secretor status.J Med Genet. 1979 Dec;16(6):423-7. doi: 10.1136/jmg.16.6.423.
• [31] Role for alpha-L-fucosidase in the control of Helicobacter pylori-infected gastric cancer cells.Proc Natl Acad Sci U S A. 2009 Aug 25;106(34):14581-6. doi: 10.1073/pnas.0903286106. Epub 2009 Aug 7.